---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-000603"
form_type: "8-K"
ticker: "ABOS"
cik: "0001576885"
company_name: "Acumen Pharmaceuticals, Inc."
filed_at: "2022-01-03T23:59:59+00:00"
generated_at: "2026-06-27T21:23:03.277086+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Acumen Pharmaceuticals amends executive employment agreements with new base salaries and severance terms

## Summary
- CEO O'Connell: $551,200 base salary; 55% bonus target; 12-month non-CIC severance, 18-month CIC severance.
- CFO Zuga: $415,300 base; 40% bonus target; 9-month non-CIC severance, 12-month CIC severance with 1.0x bonus lump sum.
- CMO Siemers ($342,000 base) and COO Barton ($299,040 base) receive same severance structure as CFO.
- CIC severance includes full acceleration of time-based equity awards in addition to cash severance and COBRA.

## SEC filing metadata
- accession: 0001193125-22-000603
- form_type: 8-K
- ticker: ABOS
- cik: 0001576885
- company_name: Acumen Pharmaceuticals, Inc.
- filed_at: 2022-01-03T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1576885/000119312522000603/0001193125-22-000603-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1576885/000119312522000603/d245848d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-000603
- JSON: https://secwatch.observer/filing/0001193125-22-000603.json
- Plain text: https://secwatch.observer/filing/0001193125-22-000603.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.